Roquette Announces Commitment to Provide New Product Offerings

New product offerings are low endotoxin, multi-compendial-grade materials for cell culture and biologic drug formulations. These products extend Roquette's commitment to helping customers save and sustain patients’ lives.

 

"As a long-time leader in excipients and active ingredients for the pharmaceutical market, Roquette is proud to be part of this major therapeutic progress and is excited to introduce several new products in the US, Europe, and Asia," said Paul Smaltz, VP of Global Business Unit Pharma.

 

"We have three new brands coming to the market under the names LYCADEX BioPharma dextrose, PEARLITOL BioPharma mannitol, and NEOSORB BioPharma sorbitol with a plan to continue adding to the portfolio," added Kelsey Achenbach, Pharma Marketing Director. "Customers now have an alternative option with a partner who is an established manufacturer and has sole custody of the supply chain when it comes to materials for biopharmaceuticals."

 

This investment reaffirms the company's strategic initiatives to develop specialties for Pharma, Food, Nutrition, and Health markets to accelerate global growth. The BioPharma market launch addresses the growing customer demand for biologic drugs worldwide. These protein-based drugs can be game-changing by having the ability to put rheumatoid arthritis into remission and transform many cancers into treatable conditions.

 

A family owned Group serving customers globally, Roquette is a leader in specialty food ingredients and pharmaceutical excipients. The products and solutions developed by the Group deliver proven technological, nutritional, and health benefits precisely tailored to the pharma, nutrition, food, and selected industry markets. Roquette's offer is produced from plant-based raw materials such as corn, wheat, potatoes, and peas. Since its foundation over 80 years ago, the Group's growth has been based on innovation, a passion for the job, and a commitment to achieve. Roquette operates in over 100 countries, has a turnover of around 3.3 billion euros, and currently employs more than 8,000 people worldwide. For more information, visit http://www.roquette.com.

 

See more at: http://drug-dev.com/Main/Current-News/1853.aspx#sthash.38JkpZcq.dpuf